Oregon State University

Jongtae Yang

David T Wong

Hui Xu

Taifo Mahmud

James David White

Zixin Deng

Linquan Bai

David B Chan

Rajan Juniku

The present disclosure concerns a compound, or a pharmaceutically acceptable salt thereof, having a formula: where at least one of R-Ris a heterocycle, at least one of R-Ris an aryl group coupled to the ring by a linker atom, functional group, or other moiety, or where none of R-Ris an amide, and any and all combinations thereof. Remaining R-Rsubstituents independently are aliphatic, substituted aliphatic, amine, substituted amine, aryl, substituted aryl, cyclic, substituted cyclic, halide, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, hydrogen or hydroxyl. A method for treating a subject also is provided comprising administering a disclosed compound or compounds, or a prodrug that is converted into the disclosed compound or compounds, or a composition comprising the compound, compounds, or prodrugs thereof, to a subject. A method for making disclosed compounds also is provided.

Inhibitor(s) of transporters or uptake of monoaminergic neurotransmitters

This disclosure relates to validamycin A biosynthesis and in particular, to methods of producing validamycin A analogs and uses thereof. In a particular example, a method for making a validamycin A analog includes transforming a host cell with one or more recombinant DNA vectors to produce a valN-inactivated mutant; and culturing the valN-inactivated mutant in a culture medium to produce a validamycin A analog, such as 1,1'-bis-valienamine and validienamycin, and their conversion to valienamine. The present disclosure further relates to compositions including such compounds as well as methods of using the compositions, such as for antifungal agents.

Methods of producing validamycin A analogs and uses thereof

Growing community of inventors

Corvallis, OR, United States of America

Jongtae Yang